SCHEDULE: FMR LLC Reports 8.5% Stake in Parabilis Medicines

FMR LLC, through its subsidiaries, has disclosed beneficial ownership of 8.5% of Parabilis Medicines Inc.'s common stock as of June 30, 2026.

Summary

• FMR LLC and Abigail P. Johnson, through various entities including FIAM LLC, Fidelity Institutional Asset Management Trust Company BK, Fidelity Management & Research Company LLC, and Fidelity Management Trust Company BK, have reported beneficial ownership of 10,292,735 shares of Parabilis Medicines Inc. common stock.
• This holding represents 8.5% of the class of securities.
• The filing is a Schedule 13G, indicating passive investment by FMR LLC and its affiliates.
• The reporting date for this ownership stake is June 30, 2026.
• Abigail P. Johnson is identified as a Director, Chairman, and CEO of FMR LLC, and members of the Johnson family are predominant owners of FMR LLC's voting shares.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a neutral filing, primarily reporting a change in beneficial ownership without new operational or financial performance data.

Positives

• FMR LLC's investment indicates confidence from a significant institutional investor in Parabilis Medicines Inc.'s long-term prospects.
• The passive nature of the filing (Schedule 13G) suggests FMR LLC is not seeking to control or influence the company's management.

Negatives

• The filing does not provide any new operational or financial performance data for Parabilis Medicines Inc.
• The information is historical, reflecting ownership as of June 30, 2026.

Risks

• As a Schedule 13G filing, it signifies a passive investment, meaning FMR LLC's stake could be reduced or divested at any time without prior notice, potentially impacting share price.
• The concentration of voting power among the Johnson family within FMR LLC, as described in Exhibit 99, could be a factor in future strategic decisions related to their investments.

Future Outlook

This filing does not contain forward-looking statements or guidance from Parabilis Medicines Inc. It solely reports on the beneficial ownership of FMR LLC.

Management Comments

• FMR LLC and Abigail P. Johnson, through their respective powers of attorney, certify that the securities were acquired and are held in the ordinary course of business and were not acquired or held for the purpose of or with the effect of changing or influencing the control of the issuer.

Industry Context

StockSavvy.ai notes that institutional investors like FMR LLC often take significant stakes in biotechnology and pharmaceutical companies, reflecting a common investment strategy in the sector. The filing of a Schedule 13G by FMR LLC suggests a passive investment approach, typical for large asset managers.

Comparison to Industry Standards

• FMR LLC is a major global asset management firm, managing trillions of dollars in assets across various funds and entities.
• The 8.5% stake in Parabilis Medicines Inc. is a notable but not controlling position for an institutional investor of FMR LLC's size.
• Other institutional investors in the pharmaceutical and biotech sector often hold similar or larger stakes in companies at various stages of development.

Stakeholder Impact

• Shareholders: The disclosure of a significant stake by FMR LLC may be viewed positively, potentially increasing investor confidence, but the passive nature means no immediate strategic impact is implied.
• Management of Parabilis Medicines Inc.: The filing does not indicate any intention by FMR LLC to influence management decisions.
• Creditors: No direct impact is indicated by this filing.

Next Steps

• FMR LLC will continue to monitor its investment in Parabilis Medicines Inc.
• Parabilis Medicines Inc. will continue its business operations and disclosures.

Key Dates

Keywords

FMR LLC, Abigail P. Johnson, Parabilis Medicines Inc., Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, Investment Management